| 摘要 |
The present invention relates to the use of PAR1 antagonists, in particular of vorapaxar, of atopaxar and of 3-(2-chlorophenyl)-1-[4-(4-fluorobenzyl)piperazin-1-yl]propenone, or a pharmaceutically acceptable salt thereof, for preventing and/or treating pelvi-perineal functional pathological conditions, and more particularly painful bladder syndrome. |
